Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
27.5M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
14M
-
Shares change
-
+1.01M
-
Total reported value, excl. options
-
$124M
-
Value change
-
+$9.26M
-
Put/Call ratio
-
0.31
-
Number of buys
-
35
-
Number of sells
-
-27
-
Price
-
$8.83
Significant Holders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) as of Q2 2023
74 filings reported holding FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value as of Q2 2023.
FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14M shares
of 27.5M outstanding shares and own 51.08% of the company stock.
Largest 10 shareholders include Southpoint Capital Advisors LP (4.08M shares), Sonic GP LLC (2.41M shares), Solas Capital Management, LLC (1.44M shares), Avoro Capital Advisors LLC (1.2M shares), DG Capital Management, LLC (1.07M shares), BlackRock Inc. (830K shares), HARBERT FUND ADVISORS, INC. (467K shares), AIGH Capital Management LLC (349K shares), 683 Capital Management, LLC (300K shares), and GENDELL JEFFREY L (283K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.